Related Experiment Video

Updated: Jun 21, 2026

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids
13:05

Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids

Published on: June 28, 2019

L-carnitine supplementation and EPO requirement in children on chronic hemodialysis

Bilal Aoun1, Etienne Bérard, Renata Vitkevic

  • 1Department of Pediatric Nephrology, Armand Trousseau Hospital, APHP, University Pierre et Marie Curie, 75012, Paris, France.

Pediatric Nephrology (Berlin, Germany)
|August 8, 2009
PubMed

Insights

Intravenous L-carnitine supplementation in pediatric hemodialysis patients increased hemoglobin levels and decreased erythropoietin (EPO) needs. This study suggests L-carnitine may benefit anemia management in these patients.

Area of Science:

  • Nephrology
  • Pediatric Nephrology
  • Nutritional Science

Background:

  • Anemia is a common complication in pediatric hemodialysis patients.
  • L-carnitine supplementation is debated for its role in managing anemia in this population.

Purpose of the Study:

  • To investigate the effect of intravenous L-carnitine on erythropoietin (EPO) requirements in pediatric hemodialysis patients.
  • To assess changes in hemoglobin (Hb) levels and free carnitine (FC) levels during L-carnitine supplementation.

Main Methods:

  • Six pediatric hemodialysis patients received intravenous L-carnitine for 9 months.
  • EPO doses were adjusted to maintain Hb levels between 11-13 g/dl.
  • FC levels were measured before, during, and after L-carnitine treatment.

Main Results:

  • EPO requirement decreased significantly from 1.15 to 0.47 microg/kg.
  • Hb levels increased from 12.2 to 14.0 g/dl within 2 months.
  • FC levels significantly increased during supplementation and remained elevated after withdrawal.

Conclusions:

  • Intravenous L-carnitine supplementation appears to increase Hb levels and reduce EPO requirements in pediatric hemodialysis patients.
  • Elevated FC levels suggest sustained carnitine availability.
  • Further multi-center studies are needed to confirm these findings due to the absence of controls.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.